Mizuho positive on Intra-Cellular Therapies (ITCI), 'potential for the stock to move even higher'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities
April 17, 2024 5:13 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.
The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More
